FDA OKs new Johnson & Johnson treatment for psoriasis
Share
Tweet
July 14, 2017
TRENTON, N.J. (AP) — U.S. regulators approved a new psoriasis drug from Johnson & Johnson Thursday, giving people with the itchy and painful condition another treatment option.
Johnson & Johnson said that in one patient study, about seven in 10 patients getting the drug, Tremfya, had clear or nearly clear skin after 24 weeks of treatment. That compares with about four in 10 patients receiving rival AbbVie's Humira, which treats several immune disorders and is the world's top selling drug.
Tremfya, which is injected every eight weeks, can cause infections and other serious side effects. Because...
For access to this article please
sign in or
subscribe.
Reader Comments(0)